Literature DB >> 28933650

Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.

Teresa Fazia1, Roberta Pastorino1, Luisa Foco2, Lide Han3, Mark Abney3, Ashley Beecham4, Athena Hadjixenofontos4, Hui Guo5, Davide Gentilini6, Charalampos Papachristou7, Pier Paolo Bitti8, Anna Ticca9, Carlo Berzuini5, Jacob L McCauley4, Luisa Bernardinelli1.   

Abstract

BACKGROUND: A wealth of single-nucleotide polymorphisms (SNPs) responsible for multiple sclerosis (MS) susceptibility have been identified; however, they explain only a fraction of MS heritability.
OBJECTIVES: We contributed to discovery of new MS susceptibility SNPs by studying a founder population with high MS prevalence.
METHODS: We analyzed ImmunoChip data from 15 multiplex families and 94 unrelated controls from the Nuoro Province, Sardinia, Italy. We tested each SNP for both association and linkage with MS, the linkage being explored in terms of identity-by-descent (IBD) sharing excess and using gene dropping to compute a corresponding empirical p-value. By targeting regions that are both associated and in linkage with MS, we increase chances of identifying interesting genomic regions.
RESULTS: We identified 486 MS-associated (p < 1 × 10-4) and 18,426 MS-linked (p < 0.05) SNPs. A total of 111 loci were both linked and associated with MS, 18 of them pointing to 14 non-major histocompatibility complex (MHC) genes, and 93 of them located in the MHC region.
CONCLUSION: We discovered new suggestive signals and confirmed some previously identified ones. We believe this to represent a significant step toward an understanding of the genetic basis of MS.

Entities:  

Keywords:  Multiple sclerosis; association; founder population; identity-by-descent sharing; pedigree

Year:  2017        PMID: 28933650     DOI: 10.1177/1352458517732841

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  Plasma Protein Levels Analysis in Multiple Sclerosis Sardinian Families Identified C9 and CYP24A1 as Candidate Biomarkers.

Authors:  Andrea Nova; Teresa Fazia; Ashley Beecham; Valeria Saddi; Marialuisa Piras; Jacob L McCauley; Carlo Berzuini; Luisa Bernardinelli
Journal:  Life (Basel)       Date:  2022-01-20

2.  Investigating the Causal Effect of Brain Expression of CCL2, NFKB1, MAPK14, TNFRSF1A, CXCL10 Genes on Multiple Sclerosis: A Two-Sample Mendelian Randomization Approach.

Authors:  Teresa Fazia; Andrea Nova; Davide Gentilini; Ashley Beecham; Marialuisa Piras; Valeria Saddi; Anna Ticca; Pierpaolo Bitti; Jacob L McCauley; Carlo Berzuini; Luisa Bernardinelli
Journal:  Front Bioeng Biotechnol       Date:  2020-05-05

3.  Homozygosity Haplotype and Whole-Exome Sequencing Analysis to Identify Potentially Functional Rare Variants Involved in Multiple Sclerosis among Sardinian Families.

Authors:  Teresa Fazia; Daria Marzanati; Anna Laura Carotenuto; Ashley Beecham; Athena Hadjixenofontos; Jacob L McCauley; Valeria Saddi; Marialuisa Piras; Luisa Bernardinelli; Davide Gentilini
Journal:  Curr Issues Mol Biol       Date:  2021-10-27       Impact factor: 2.976

4.  Heritability Estimation of Multiple Sclerosis Related Plasma Protein Levels in Sardinian Families with Immunochip Genotyping Data.

Authors:  Andrea Nova; Giulia Nicole Baldrighi; Teresa Fazia; Francesca Graziano; Valeria Saddi; Marialuisa Piras; Ashley Beecham; Jacob L McCauley; Luisa Bernardinelli
Journal:  Life (Basel)       Date:  2022-07-21

5.  Haemolymphatic cancer among children in Sardinia, Italy: 1974-2003 incidence.

Authors:  Giorgio Broccia; Jonathan Carter; Cansu Ozsin-Ozler; Federico Meloni; Ilaria Pilia; Giannina Satta; Giulio Murgia; Marcello Campagna; Pierluigi Cocco
Journal:  BMJ Open       Date:  2020-11-03       Impact factor: 2.692

6.  Incidence of non-Hodgkin's lymphoma among adults in Sardinia, Italy.

Authors:  Giorgio Broccia; Jonathan Carter; Cansu Ozsin-Ozler; Federico Meloni; Sara De Matteis; Pierluigi Cocco
Journal:  PLoS One       Date:  2022-02-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.